← Back to patent-cliff list
Bimatoprost-Drug Ring System (Spyglass Pharma)
Tier C — Watch / tradeBimatoprost-Drug Ring System (Spyglass Pharma)
Spyglass Pharma Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Prostanoid receptor
Indications (approved)：白内障, Ocular hypertension, Glaucoma
Regional status
US
Phase III
2025-10-15
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Bimatoprost-Drug Ring System (Spyglass Pharma)?
Approved indications include: 白内障, Ocular hypertension, Glaucoma.
When does the Bimatoprost-Drug Ring System (Spyglass Pharma) patent expire?
No public expiry year is available for Bimatoprost-Drug Ring System (Spyglass Pharma) yet; this page updates once verified.
How do I get a quote for Bimatoprost-Drug Ring System (Spyglass Pharma) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30